Pelthos Therapeutics (PTHS) Price to Sales (2025 - 2026)

Pelthos Therapeutics (PTHS) posted Price to Sales of 3.96 for Q2 2026, down 38.94% on a QoQ basis from 6.49 in Q1 2026.

Analysis

Pelthos Therapeutics (PTHS) Price to Sales (2025 - 2026) Analysis & Trends

Pelthos Therapeutics has reported Price to Sales for 2 years, with the latest figure at 3.96 in Q2 2026.

On a quarterly basis, Price to Sales changed N/A year-over-year to 3.96 in Q2 2026; TTM through Jun 2026 was 1.95, a N/A change from a year earlier, with the FY2026 full-year figure at 2.48, changed N/A from the prior year.
Price to Sales was 3.96 for Q2 2026 at Pelthos Therapeutics, down from 6.49 in the prior quarter.
The five-year high for Price to Sales was 11.69 in Q3 2025, with the low at 3.96 in Q2 2026.

Peer Set

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Johnson & Johnson	641.30 Bn	620.54 Bn	17.26 Bn
2	AbbVie	446.34 Bn	439.77 Bn	12.70 Bn
3	Merck	357.25 Bn	350.11 Bn	12.21 Bn
4	Novartis Ag	268.57 Bn	260.88 Bn	11.24 Bn
5	Pfizer	156.47 Bn	144.77 Bn	10.94 Bn
6	Sanofi	52.23 Bn	44.85 Bn	10.79 Bn
7	Revolution Medicines	43.14 Bn	43.14 Bn	-
8	Incyte	24.83 Bn	20.29 Bn	1.57 Bn
9	United Therapeutics	21.31 Bn	18.64 Bn	683.80 Mn
10	Pelthos Therapeutics	80.38 Mn	55.82 Mn	21.23 Mn

Historic Data

Download Data